Isomorphic Labs, the DeepMind spin‑out, begins fundraising talks that could push its valuation toward $50 billion
The AI‑driven drug discovery firm, recently separated from Alphabet’s DeepMind, is in early discussions for a new financing round that may value the company at up to $50 billion.